Theravance Biopharma Files 8-K on Operations

Ticker: TBPH · Form: 8-K · Filed: Aug 12, 2025 · CIK: 1583107

Theravance Biopharma, Inc. 8-K Filing Summary
FieldDetail
CompanyTheravance Biopharma, Inc. (TBPH)
Form Type8-K
Filed DateAug 12, 2025
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.00001
Sentimentneutral

Sentiment: neutral

Topics: operations, financials, filing

TL;DR

Theravance Biopharma dropped an 8-K on Aug 12th covering financials and operations.

AI Summary

Theravance Biopharma, Inc. filed an 8-K on August 12, 2025, to report on its results of operations and financial condition. The filing also includes financial statements and exhibits. The company is incorporated in the Cayman Islands and its principal executive offices are located in South San Francisco, California.

Why It Matters

This 8-K filing provides an update on Theravance Biopharma's financial performance and operational status, which is crucial for investors to assess the company's health and future prospects.

Risk Assessment

Risk Level: low — This filing is a routine 8-K reporting operational and financial information, not indicating any immediate or significant adverse events.

Key Players & Entities

  • Theravance Biopharma, Inc. (company) — Registrant
  • August 12, 2025 (date) — Date of earliest event Reported
  • Cayman Islands (jurisdiction) — State or Other Jurisdiction of Incorporation
  • 901 Gateway Boulevard South San Francisco , CA 94080 (address) — Principal executive offices
  • 650-808-6000 (phone_number) — Business phone number

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report on Theravance Biopharma, Inc.'s Results of Operations and Financial Condition, as well as to include Financial Statements and Exhibits.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on August 12, 2025.

Where is Theravance Biopharma, Inc. incorporated?

Theravance Biopharma, Inc. is incorporated in the Cayman Islands.

What is the Commission File Number for Theravance Biopharma, Inc.?

The Commission File Number for Theravance Biopharma, Inc. is 001-36033.

What is the business address and phone number for Theravance Biopharma, Inc.?

The business address is C/O Theravance Biopharma US, LLC, 901 Gateway Boulevard South San Francisco, CA 94080, and the business phone number is (650) 808-6000.

Filing Stats: 566 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2025-08-12 16:11:52

Key Financial Figures

  • $0.00001 — e on which registered Ordinary Share $0.00001 Par Value TBPH NASDAQ Global Marke

Filing Documents

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. On August 12, 2025, Theravance Biopharma, Inc. (the "Company") issued a press release and is holding a conference call regarding its financial results for the quarter ended June 30, 2025, and a business update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report and a copy of materials that will accompany the call is furnished as Exhibit 99.2 to this Current Report. The information in Item 2.02 and in Item 9.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Securities Exchange Act of 1934"), or otherwise subject to the liabilities of that Section, nor shall it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as expressly set forth by specific reference in such a filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. 99.1 Press Release dated August 12, 2025 99.2 Slide deck entitled Second Quarter 2025 Financial Results and Business Update 104 Cover Page Interactive Data File (cover page XBRL tags embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. THERAVANCE BIOPHARMA, INC. Date: August 12, 2025 By: /s/ Aziz Sawaf Aziz Sawaf Senior Vice President and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.